PMC:7200337 / 91632-91877 JSONTXT

{"project":"LitCovid-PD-FMA-UBERON","denotations":[{"id":"T723","span":{"begin":101,"end":109},"obj":"Body_part"}],"attributes":[{"id":"A723","pred":"fma_id","subj":"T723","obj":"http://purl.org/sig/ont/fma/fma62871"}],"text":"The commercial anti-IL-6R antibodies tocilizumab (Actemra) and sarilumab (Kevzara) and the anti-IL-6 antibody siltuximab (Sylvant) are now being tested for efficacy in managing COVID-19 CRS and pneumonia in 13 ongoing clinical trials (Table 2 )."}

{"project":"LitCovid-PD-MONDO","denotations":[{"id":"T523","span":{"begin":177,"end":185},"obj":"Disease"},{"id":"T524","span":{"begin":186,"end":189},"obj":"Disease"},{"id":"T526","span":{"begin":194,"end":203},"obj":"Disease"}],"attributes":[{"id":"A523","pred":"mondo_id","subj":"T523","obj":"http://purl.obolibrary.org/obo/MONDO_0100096"},{"id":"A524","pred":"mondo_id","subj":"T524","obj":"http://purl.obolibrary.org/obo/MONDO_0007399"},{"id":"A525","pred":"mondo_id","subj":"T524","obj":"http://purl.obolibrary.org/obo/MONDO_0017361"},{"id":"A526","pred":"mondo_id","subj":"T526","obj":"http://purl.obolibrary.org/obo/MONDO_0005249"}],"text":"The commercial anti-IL-6R antibodies tocilizumab (Actemra) and sarilumab (Kevzara) and the anti-IL-6 antibody siltuximab (Sylvant) are now being tested for efficacy in managing COVID-19 CRS and pneumonia in 13 ongoing clinical trials (Table 2 )."}

{"project":"LitCovid-PD-CLO","denotations":[{"id":"T957","span":{"begin":145,"end":151},"obj":"http://purl.obolibrary.org/obo/UBERON_0000473"}],"text":"The commercial anti-IL-6R antibodies tocilizumab (Actemra) and sarilumab (Kevzara) and the anti-IL-6 antibody siltuximab (Sylvant) are now being tested for efficacy in managing COVID-19 CRS and pneumonia in 13 ongoing clinical trials (Table 2 )."}

{"project":"LitCovid-PD-CHEBI","denotations":[{"id":"T290","span":{"begin":20,"end":22},"obj":"Chemical"},{"id":"T292","span":{"begin":37,"end":48},"obj":"Chemical"},{"id":"T293","span":{"begin":96,"end":98},"obj":"Chemical"}],"attributes":[{"id":"A290","pred":"chebi_id","subj":"T290","obj":"http://purl.obolibrary.org/obo/CHEBI_63895"},{"id":"A291","pred":"chebi_id","subj":"T290","obj":"http://purl.obolibrary.org/obo/CHEBI_74072"},{"id":"A292","pred":"chebi_id","subj":"T292","obj":"http://purl.obolibrary.org/obo/CHEBI_64360"},{"id":"A293","pred":"chebi_id","subj":"T293","obj":"http://purl.obolibrary.org/obo/CHEBI_63895"},{"id":"A294","pred":"chebi_id","subj":"T293","obj":"http://purl.obolibrary.org/obo/CHEBI_74072"}],"text":"The commercial anti-IL-6R antibodies tocilizumab (Actemra) and sarilumab (Kevzara) and the anti-IL-6 antibody siltuximab (Sylvant) are now being tested for efficacy in managing COVID-19 CRS and pneumonia in 13 ongoing clinical trials (Table 2 )."}

{"project":"LitCovid-PD-HP","denotations":[{"id":"T55","span":{"begin":194,"end":203},"obj":"Phenotype"}],"attributes":[{"id":"A55","pred":"hp_id","subj":"T55","obj":"http://purl.obolibrary.org/obo/HP_0002090"}],"text":"The commercial anti-IL-6R antibodies tocilizumab (Actemra) and sarilumab (Kevzara) and the anti-IL-6 antibody siltuximab (Sylvant) are now being tested for efficacy in managing COVID-19 CRS and pneumonia in 13 ongoing clinical trials (Table 2 )."}

{"project":"LitCovid-PD-GO-BP","denotations":[{"id":"T204","span":{"begin":20,"end":25},"obj":"http://purl.obolibrary.org/obo/GO_0004915"}],"text":"The commercial anti-IL-6R antibodies tocilizumab (Actemra) and sarilumab (Kevzara) and the anti-IL-6 antibody siltuximab (Sylvant) are now being tested for efficacy in managing COVID-19 CRS and pneumonia in 13 ongoing clinical trials (Table 2 )."}

{"project":"LitCovid-PubTator","denotations":[{"id":"3026","span":{"begin":20,"end":25},"obj":"Gene"},{"id":"3027","span":{"begin":96,"end":100},"obj":"Gene"},{"id":"3035","span":{"begin":37,"end":48},"obj":"Chemical"},{"id":"3036","span":{"begin":63,"end":72},"obj":"Chemical"},{"id":"3037","span":{"begin":74,"end":81},"obj":"Chemical"},{"id":"3044","span":{"begin":177,"end":185},"obj":"Disease"},{"id":"3045","span":{"begin":194,"end":203},"obj":"Disease"}],"attributes":[{"id":"A3026","pred":"tao:has_database_id","subj":"3026","obj":"Gene:3570"},{"id":"A3027","pred":"tao:has_database_id","subj":"3027","obj":"Gene:3569"},{"id":"A3035","pred":"tao:has_database_id","subj":"3035","obj":"MESH:C502936"},{"id":"A3036","pred":"tao:has_database_id","subj":"3036","obj":"MESH:C000592401"},{"id":"A3037","pred":"tao:has_database_id","subj":"3037","obj":"MESH:C000592401"},{"id":"A3044","pred":"tao:has_database_id","subj":"3044","obj":"MESH:C000657245"},{"id":"A3045","pred":"tao:has_database_id","subj":"3045","obj":"MESH:D011014"}],"namespaces":[{"prefix":"Tax","uri":"https://www.ncbi.nlm.nih.gov/taxonomy/"},{"prefix":"MESH","uri":"https://id.nlm.nih.gov/mesh/"},{"prefix":"Gene","uri":"https://www.ncbi.nlm.nih.gov/gene/"},{"prefix":"CVCL","uri":"https://web.expasy.org/cellosaurus/CVCL_"}],"text":"The commercial anti-IL-6R antibodies tocilizumab (Actemra) and sarilumab (Kevzara) and the anti-IL-6 antibody siltuximab (Sylvant) are now being tested for efficacy in managing COVID-19 CRS and pneumonia in 13 ongoing clinical trials (Table 2 )."}

{"project":"LitCovid-sentences","denotations":[{"id":"T521","span":{"begin":0,"end":245},"obj":"Sentence"}],"namespaces":[{"prefix":"_base","uri":"http://pubannotation.org/ontology/tao.owl#"}],"text":"The commercial anti-IL-6R antibodies tocilizumab (Actemra) and sarilumab (Kevzara) and the anti-IL-6 antibody siltuximab (Sylvant) are now being tested for efficacy in managing COVID-19 CRS and pneumonia in 13 ongoing clinical trials (Table 2 )."}